Prevention of Ebola virus disease through vaccination: where we are in 2018
Lancet
.
2018 Sep 1;392(10149):787-790.
doi: 10.1016/S0140-6736(18)31710-0.
Epub 2018 Aug 10.
Authors
Yves Lévy
1
,
Clifford Lane
2
,
Peter Piot
3
,
Abdul Habib Beavogui
4
,
Mark Kieh
5
,
Bailah Leigh
6
,
Seydou Doumbia
7
,
Eric D'Ortenzio
8
,
Claire Lévy-Marchal
8
,
Jerome Pierson
2
,
Deborah Watson-Jones
3
,
Vinh-Kim Nguyen
9
,
Heidi Larson
3
,
Julia Lysander
5
,
Christine Lacabaratz
8
,
Rodolphe Thiebaut
8
,
Augustin Augier
10
,
David Ishola
3
,
Stephen Kennedy
5
,
Geneviève Chêne
8
,
Brian Greenwood
3
,
James Neaton
11
,
Yazdan Yazdanpanah
8
Affiliations
1
French Institute for Health and Medical Research (Inserm), Paris, France. Electronic address: yves.levy@inserm.fr.
2
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
3
London School of Hygiene & Tropical Medicine, London, UK.
4
Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Mafèrinyah, Guinea.
5
Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
6
College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone.
7
University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
8
French Institute for Health and Medical Research (Inserm), Paris, France.
9
Graduate Institute of International and Development Studies, Geneva, Switzerland.
10
The Alliance for International Medical Action, Dakar, Senegal.
11
School of Public Health, University of Minnesota, Minneapolis, MN, USA.
PMID:
30104048
PMCID:
PMC6128979
DOI:
10.1016/S0140-6736(18)31710-0
No abstract available
MeSH terms
Ebola Vaccines* / adverse effects
Ebola Vaccines* / immunology
Hemorrhagic Fever, Ebola / prevention & control*
Humans
Randomized Controlled Trials as Topic
Vaccination*
Substances
Ebola Vaccines
Grants and funding
Z99 AI999999/Intramural NIH HHS/United States
ZID AI009001-07/Intramural NIH HHS/United States
ZID AI009001-08/Intramural NIH HHS/United States